 MELBOURNE, Australia, Sept. 23, 2021 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021. 